Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies
暂无分享,去创建一个
E. Hannan | J. Tu | K. Harjai | G. Stone | Seung‐Jung Park | A. Kirtane | J. Moses | M. Leon | S. Iyengar | R. Mehran | A. Lansky | B. Brodie | R. Waksman | R. Applegate | L. Jensen | M. Racz | Anuj Gupta | F. Saia | Michael J. Racz | R. Perry | R. Waksman
[1] Frederic S. Resnic,et al. Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts , 2008, Circulation.
[2] K. Harjai,et al. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study). , 2008, Journal of interventional cardiology.
[3] E. Hannan. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. , 2008, JACC. Cardiovascular interventions.
[4] Laura Mauri,et al. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. , 2008, Journal of the American College of Cardiology.
[5] H. Putter,et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. , 2008, Journal of the American College of Cardiology.
[6] A. Jeremias,et al. Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention , 2008, Annals of Internal Medicine.
[7] K. Kent,et al. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. , 2008, The American journal of cardiology.
[8] W. Little,et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. , 2008, Journal of the American College of Cardiology.
[9] R. Wilensky,et al. A comparison of bare-metal and drug-eluting stents for off-label indications. , 2008, The New England journal of medicine.
[10] Jeffrey L. Anderson,et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. , 2008, Journal of the American College of Cardiology.
[11] F. Schmidt. Meta-Analysis , 2008 .
[12] C. Perucci,et al. RESTEM: a percutaneous coronary intervention ‘real world’ registry in the drug-eluting stent era , 2007, Coronary artery disease.
[13] John Bresnahan,et al. Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.
[14] R. Blindt,et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. , 2007, The American journal of cardiology.
[15] H. Bøtker,et al. Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] A. Shah,et al. Abstract 2567: Paclitaxel Eluting Stents are associated with a high rate of Stent Thrombosis compared to Bare Metal Stents in an Underserved Hispanic Population Presenting with Acute ST Segment Myocardial Infarction , 2007 .
[17] T. Ryan,et al. Abstract 2989: Revascularization Rates In Patients With Multivessel Disease In Northern New England: How Much Better Are Drug Eluting Stents? , 2007 .
[18] H. Drexler,et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. , 2007, Journal of the American College of Cardiology.
[19] Ron Goeree,et al. Effectiveness and safety of drug-eluting stents in Ontario. , 2007, The New England journal of medicine.
[20] S. Ellis,et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. , 2007, The Journal of invasive cardiology.
[21] A. Lerman,et al. The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[22] I. Palacios,et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. , 2007, European heart journal.
[23] R. Costa,et al. Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels. , 2007, American heart journal.
[24] F. Fernández‐Avilés,et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. , 2007, European heart journal.
[25] R. Ferrari,et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. , 2007, Journal of the American College of Cardiology.
[26] P. Shah,et al. Comparison of drug‐eluting stents with bare metal stents in unselected patients with acute myocardial infarction , 2007 .
[27] Ángel Martínez,et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. , 2007, American heart journal.
[28] G. Percoco,et al. Long-Term Safety and Efficacy of Drug-Eluting Stents: Two-Year Results of the REAL (REgistro AngiopLastiche dell’Emilia Romagna) Multicenter Registry , 2007, Circulation.
[29] Antonio Colombo,et al. Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation , 2007, Circulation.
[30] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[31] Arianna Azzellino,et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). , 2007, Journal of the American College of Cardiology.
[32] J. Granada,et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.
[33] A. Branzi,et al. Randomized comparative trial of a thin‐strut bare metal cobalt‐chromium stent versus a sirolimus‐eluting stent for coronary revascularization , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[34] S. Pocock,et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.
[35] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[36] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[37] David O. Williams,et al. Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry , 2006, Circulation.
[38] E. Bramucci,et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.
[39] B. Yan,et al. The clinical outcome of restricting drug-eluting stents to patients at highest risk of restenosis. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[40] C. Xie,et al. Primary and rescue percutaneous coronary intervention with paclitaxel-eluting stent implantation in ST-elevation myocardial infarction. , 2006, American Journal of Cardiology.
[41] Joseph P Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[42] I. Iakovou,et al. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. , 2005, American heart journal.
[43] Gregg W Stone,et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.
[44] P. Serruys,et al. Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[45] A. Kastrati,et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. , 2005, European heart journal.
[46] J. Popma,et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.
[47] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[48] William Wijns,et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.
[49] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[50] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[51] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[52] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[53] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[54] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[55] B. Gersh. A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications , 2008 .